Vis enkel innførsel

dc.contributor.authorGerritzen, Matthias J.H.
dc.contributor.authorSalverda, Merijn LM
dc.contributor.authorMartens, Dirk E.
dc.contributor.authorWijffels, Rene Hubertus
dc.contributor.authorStork, Michiel
dc.date.accessioned2020-06-17T11:45:20Z
dc.date.available2020-06-17T11:45:20Z
dc.date.created2019-10-15T16:48:00Z
dc.date.issued2019
dc.identifier.citationGerritzen, M. J. H., Salverda, M. L. M., Martens, D. E., Wijffels, R. H. & Stork, M. (2019). Spontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform: production and purification. Vaccine, 37(47), 6978-6986. doi:en_US
dc.identifier.issn1873-2518
dc.identifier.urihttps://hdl.handle.net/11250/2658470
dc.description.abstractOuter membrane vesicles (OMVs) are nanoparticles produced by Gram-negative bacteria that can be used as vaccines. The application of OMVs as vaccine component can be expanded by expressing heterologous antigens on OMVs, creating an OMV-based antigen presenting platform. This study aims to develop a production process for such OMV-based vaccines and studies a production method based on meningococcal OMVs that express heterologous antigens on their surface. As a proof of concept, the Borrelia burgdorferi antigens OspA and OspC were expressed on Neisseria meningitidis OMVs to create a concept anti-Lyme disease vaccine. Production of OMVs released in the culture supernatant was induced by high dissolved oxygen concentrations and purification was based on scalable unit operations. A crude recovery of 90 mg OMV protein could be obtained per liter culture. Expressing heterologous antigens on the OMVs did result in minor reduction of bacterial growth, while OMV production remained constant. The antigen expression did not alter the OMV characteristics. This study shows that production of well characterized OMVs containing heterologous antigens is possible with high yields by combining high oxygen concentrations with an optimized purification process. It is concluded that heterologous OMVs show potential as a vaccine platform.en_US
dc.language.isoengen_US
dc.publisherElsevieren_US
dc.rightsNavngivelse 4.0 Internasjonal*
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/deed.no*
dc.titleSpontaneously released Neisseria meningitidis outer membrane vesicles as vaccine platform : production and purificationen_US
dc.typePeer revieweden_US
dc.typeJournal articleen_US
dc.description.versionpublishedVersionen_US
dc.rights.holder© 2019 The Author(s)en_US
dc.subject.nsiVDP::Medisinske Fag: 700::Basale medisinske, odontologiske og veterinærmedisinske fag: 710::Medisinsk immunologi: 716en_US
dc.source.pagenumber6978-6986en_US
dc.source.volume37en_US
dc.source.journalVaccineen_US
dc.source.issue47en_US
dc.identifier.doi10.1016/j.vaccine.2019.01.076
dc.identifier.cristin1737318
dc.description.localcodeUnit Licence Agreementen_US


Tilhørende fil(er)

Thumbnail

Denne innførselen finnes i følgende samling(er)

Vis enkel innførsel

Navngivelse 4.0 Internasjonal
Med mindre annet er angitt, så er denne innførselen lisensiert som Navngivelse 4.0 Internasjonal